NCT01273766 · STUDY IN CONTEXT

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Changes in Neutrophils between baseline and mean neutrophils values during treatment (measured after each dose)

Source null

→

secondary · POSTED

Records will be assessed at baseline and prospectively while on study.

Number analyzed in rows differs from overall because data was not collected on all participants.

→

secondary · POSTED

Records will be assessed at baseline and prospectively while on study.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-acute-undifferentiated-leukemia
nct id: NCT01273766
trial label: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 3
harms Count: 3
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0000
source section id
NCT01273766-om-0000
source outcome index
0
endpoint
Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only)
endpoint definition
Changes in Neutrophils between baseline and mean neutrophils values during treatment (measured after each dose)
time origin
Baseline, up to 6 months
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0001
source section id
NCT01273766-om-0001
source outcome index
1
endpoint
Need for Hospitalization, Ventilator Support, Exchange Transfusion/Apheresis or Treatment With Antifungals or Antibiotics
endpoint definition
Records will be assessed at baseline and prospectively while on study.
time origin
Baseline, up to 6 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Number analyzed in rows differs from overall because data was not collected on all participants.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0002
source section id
NCT01273766-om-0002
source outcome index
2
endpoint
Cumulative Incidence of Documented Bacterial, Fungal, and Viral Infections
endpoint definition
Records will be assessed at baseline and prospectively while on study.
time origin
Baseline, up to 6 months
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0000
arm key
OG000
arm label
Arm I
regimen
Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity. deferasirox : Given orally laboratory biomarker analysis : Correlative studies enzyme-linked immunosorbent assay : Correlative studies
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01273766-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0001
arm key
OG000
arm label
Arm I
regimen
Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity. deferasirox : Given orally laboratory biomarker analysis : Correlative studies enzyme-linked immunosorbent assay : Correlative studies
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01273766-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0001
arm key
OG001
arm label
Correlative
regimen
treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01273766-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0002
arm key
OG000
arm label
Arm I
regimen
Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity. deferasirox : Given orally laboratory biomarker analysis : Correlative studies enzyme-linked immunosorbent assay : Correlative studies
analyzed count
4
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01273766-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
outcome key
om-0002
arm key
OG001
arm label
Correlative
regimen
treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT01273766-om-0002#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
harm key
EG000
source section id
NCT01273766-ae
event group key
EG000
event group label
Arm I
serious affected
4
serious at risk
4
other affected
4
other at risk
4
frequency threshold
5
collection period
6 months
event definition
only patients on Arm I (recieving drug on protocol) were tracked for toxicities
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
harm key
EG001
source section id
NCT01273766-ae
event group key
EG001
event group label
Control Arm
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
5
collection period
6 months
event definition
only patients on Arm I (recieving drug on protocol) were tracked for toxicities
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-undifferentiated-leukemia
nct id
NCT01273766
harm key
EG002
source section id
NCT01273766-ae
event group key
EG002
event group label
Correlative
serious affected
0
serious at risk
0
other affected
0
other at risk
0
frequency threshold
5
collection period
6 months
event definition
only patients on Arm I (recieving drug on protocol) were tracked for toxicities
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice